

# Olivier Sitbon

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3325579/olivier-sitbon-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

295  
papers

26,284  
citations

74  
h-index

158  
g-index

377  
ext. papers

31,669  
ext. citations

8.1  
avg. IF

6.5  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 295 | Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers.. <i>Pulmonary Circulation</i> , <b>2022</b> , 12, e12023  | 2.7  |           |
| 294 | ERS statement on chronic thromboembolic pulmonary hypertension. <i>Pulmonologiya</i> , <b>2022</b> , 32, 13-52   | 0.8  |           |
| 293 | Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 851935                 | 4.9  | 0         |
| 292 | ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. <i>ERJ Open Research</i> , <b>2022</b> , 8, 00665-2021  | 3.5  | 0         |
| 291 | To be or not to be treated with initial combination therapy, that is the (PAH) question. <i>European Respiratory Journal</i> , <b>2022</b> , 59, 2200390   | 13.6 |           |
| 290 | ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2021</b> , 57,  | 13.6 | 70        |
| 289 | Screening for pulmonary arterial hypertension in adults carrying a mutation. <i>European Respiratory Journal</i> , <b>2021</b> , 58,   | 13.6 | 11        |
| 288 | Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. <i>Advances in Therapy</i> , <b>2021</b> , 39, 796 | 4.1  | 4         |
| 287 | External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. <i>European Respiratory Journal</i> , <b>2021</b> ,   | 13.6 | 4         |
| 286 | The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. <i>European Journal of Heart Failure</i> , <b>2021</b> ,              | 12.3 | 1         |
| 285 | TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211057071        | 2.7  | 3         |
| 284 | The isobaric pulmonary arterial compliance in pulmonary hypertension. <i>ERJ Open Research</i> , <b>2021</b> , 7,  | 3.5  | 1         |
| 283 | Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 2045894021996930                                      | 2.7  | 1         |
| 282 | Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. <i>European Respiratory Journal</i> , <b>2021</b> , 58,  | 13.6 | 22        |
| 281 | Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. <i>European Respiratory Journal</i> , <b>2021</b> , 58,   | 13.6 | 2         |
| 280 | Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 842-854           | 10.2 | 13        |
| 279 | Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. <i>European Respiratory Journal</i> , <b>2021</b> , 58,            | 13.6 | 1         |

|     |  |      |    |
|-----|--|------|----|
| 278 | Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , <b>2021</b> , 41, 1549-1562  | 5.7  | 2  |
| 277 | French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 322  | 4.2  | 3  |
| 276 | Current and future treatments of pulmonary arterial hypertension. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 6-30   | 8.6  | 42 |
| 275 | Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. <i>European Respiratory Journal</i> , <b>2021</b> , 57,   | 13.6 | 3  |
| 274 | Characteristics and Long-term Outcomes of Pulmonary Venocclusive Disease Induced by Mitomycin C. <i>Chest</i> , <b>2021</b> , 159, 1197-1207   | 5.3  | 5  |
| 273 | Riociguat: Clinical research and evolving role in therapy. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 2645-2662   | 3.8  | 7  |
| 272 | Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , <b>2021</b> , 178, 106220                      | 4.6  | 10 |
| 271 | Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 238-239                             | 13.4 |    |
| 270 | Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pi e de R sistance?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 524-525                     | 10.2 | 0  |
| 269 | Reversible pulmonary hypertension associated with multivisceral Whipple's disease. <i>European Respiratory Journal</i> , <b>2021</b> , 57,   | 13.6 |    |
| 268 | Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. <i>Chest</i> , <b>2021</b> , 160, 277-286                     | 5.3  | 4  |
| 267 | Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 1306-1315   | 4.7  | 0  |
| 266 | Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 1009-1018 | 5.8  | 1  |
| 265 | Pulmonary hypertension associated with busulfan. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211030170  | 7.7  | 1  |
| 264 | Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1393-1403                         | 15.1 | 16 |
| 263 | Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2021</b> , 58,  | 13.6 | 6  |
| 262 | Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,                                 | 10.2 | 2  |
| 261 | Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2020</b> , 56,  | 13.6 | 12 |

|     |  |      |    |
|-----|--|------|----|
| 260 | Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, e90-e91   | 10.2 |    |
| 259 | Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 843-852  | 10.2 | 4  |
| 258 | Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. <i>European Respiratory Journal</i> , <b>2020</b> , 56,   | 13.6 | 11 |
| 257 | Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution. <i>European Respiratory Journal</i> , <b>2020</b> , 55,   | 13.6 | 6  |
| 256 | Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis. <i>Liver Transplantation</i> , <b>2020</b> , 26, 935-940   | 4.5  | 7  |
| 255 | Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. <i>European Respiratory Journal</i> , <b>2020</b> , 55,   | 13.6 | 11 |
| 254 | Portopulmonary hypertension in the current era of pulmonary hypertension management. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 130-139  | 13.4 | 28 |
| 253 | Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 300-309  | 5.8  | 19 |
| 252 | Hereditary hemorrhagic telangiectasia and liver involvement: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFLF), and ERN-rare liver. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2020</b> , 44, 426-432 | 2.4  | 2  |
| 251 | Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. <i>International Journal of Clinical Pharmacy</i> , <b>2020</b> , 42, 1128-1138  | 2.3  | 0  |
| 250 | Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations. <i>Respiratory Medicine</i> , <b>2020</b> , 79-96  | 0.2  | 1  |
| 249 | Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. <i>Archivos De Bronconeumologia</i> , <b>2020</b> , 56, 578-585  | 0.7  | 6  |
| 248 | Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , <b>2020</b> , 157, 955-965   | 5.3  | 14 |
| 247 | Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2020</b> , 55,   | 13.6 | 16 |
| 246 | Survival Improved in Patients Aged $\geq 70$ Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. <i>Chest</i> , <b>2020</b> , 157, 945-954  | 5.3  | 5  |
| 245 | Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020962960   | 2.7  | 4  |
| 244 | Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. <i>British Journal of Anaesthesia</i> , <b>2020</b> , 125, e466-e468  | 5.4  | 1  |
| 243 | The dangerous and contradictory prognostic significance of PVR. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 2398-2405  | 3.7  | 2  |

|     |   |      |    |
|-----|---|------|----|
| 242 | Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. <i>European Respiratory Journal</i> , <b>2020</b> , 56,   | 13.6 | 57 |
| 241 | Exercise Hemodynamics in the Prognosis of Patients with Pulmonary Arterial Hypertension. <i>Respiration</i> , <b>2020</b> , 99, 678-685   | 3.7  | 1  |
| 240 | Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. <i>Archivos De Bronconeumologia</i> , <b>2020</b> , 56, 578-585   | 0.7  | 0  |
| 239 | Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , <b>2020</b> , 177, 106241   | 4.6  | 4  |
| 238 | Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2019</b> , 155, 991-998  | 5.3  | 12 |
| 237 | Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e005095   | 5.8  | 5  |
| 236 | Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, 833-842  | 5.8  | 32 |
| 235 | French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,   | 13.6 | 82 |
| 234 | Assembly 13: placing the pulmonary circulation in the heart of ERS. <i>Breathe</i> , <b>2019</b> , 15, 88-89  | 1.8  | 0  |
| 233 | Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2019</b> , 139, 2440-2450   | 16.7 | 32 |
| 232 | Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. <i>American Journal of Pathology</i> , <b>2019</b> , 189, 1159-1175  | 5.8  | 14 |
| 231 | Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 594-604                                      | 35.1 | 61 |
| 230 | Management of pulmonary arterial hypertension in patients aged over 65 years. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, K29-K36   | 1.5  | 5  |
| 229 | Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. <i>European Respiratory Journal</i> , <b>2019</b> , 54,   | 13.6 | 8  |
| 228 | Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 227-238   | 35.1 | 55 |
| 227 | Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 352-359 | 12.3 | 26 |
| 226 | Clinical trial design and new therapies for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,  | 13.6 | 81 |
| 225 | Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. <i>Respiration</i> , <b>2018</b> , 95, 244-250   | 3.7  | 7  |

|     |  |      |    |
|-----|--|------|----|
| 224 | Outcome of Portopulmonary Hypertension After Liver Transplantation: Perhaps Not So Optimistic. <i>Transplantation</i> , <b>2018</b> , 102, e190-e191   | 1.8  | 0  |
| 223 | Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 752-763  | 15.1 | 50 |
| 222 | RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. <i>Lung</i> , <b>2018</b> , 196, 157-164   | 2.9  | 22 |
| 221 | The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 860-868  | 10.2 | 27 |
| 220 | Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. <i>American Journal of Cardiovascular Drugs</i> , <b>2018</b> , 18, 37-47        | 4    | 39 |
| 219 | Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 537-541   | 10.2 | 5  |
| 218 | Risk assessment in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2018</b> , 51,  | 13.6 | 14 |
| 217 | Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 647-655   | 5.8  | 31 |
| 216 | Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 401-408 | 5.8  | 12 |
| 215 | Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2018</b> , 137, 693-704   | 16.7 | 92 |
| 214 | Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry. <i>Chest</i> , <b>2018</b> , 153, 143-151   | 5.3  | 35 |
| 213 | Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2018</b> , 154, 882-892   | 5.3  | 7  |
| 212 | Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 1102-1110  | 5.8  | 15 |
| 211 | Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. <i>International Journal of Clinical Pharmacy</i> , <b>2018</b> , 40, 790-794  | 2.3  | 3  |
| 210 | Risk stratification in pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , <b>2018</b> , 24, 407-415   | 3    | 8  |
| 209 | Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) <b>2018</b> ,  |      | 3  |
| 208 | Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , <b>2018</b> , 13, e0193226  | 3.7  | 17 |
| 207 | Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. <i>European Respiratory Journal</i> , <b>2018</b> , 52,  | 13.6 | 15 |

|     |   |      |    |
|-----|---|------|----|
| 206 | Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2018</b> , 52,  | 13.6 | 37 |
| 205 | Pulmonary hypertension associated with neurofibromatosis type 1. <i>European Respiratory Review</i> , <b>2018</b> , 27,   | 9.8  | 18 |
| 204 | Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197112  | 3.7  | 24 |
| 203 | Factors predicting outcome after pulmonary endarterectomy. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198198   | 3.7  | 16 |
| 202 | Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2018</b> , 154, 872-881   | 5.3  | 22 |
| 201 | Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 399-406            | 5.8  | 8  |
| 200 | Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 125-134                            | 35.1 | 76 |
| 199 | Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. <i>Archives of Cardiovascular Diseases</i> , <b>2017</b> , 110, 303-316 | 2.7  | 31 |
| 198 | Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. <i>European Respiratory Review</i> , <b>2017</b> , 26,   | 9.8  | 40 |
| 197 | Gut-Lung Connection in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2017</b> , 56, 402-405   | 5.7  | 25 |
| 196 | Pulmonary hypertension due to left heart disease. <i>Archives of Cardiovascular Diseases</i> , <b>2017</b> , 110, 420-431.  | 7    |    |
| 195 | Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 717-726   | 35.1 | 62 |
| 194 | Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 104, 404-411  | 2.7  | 15 |
| 193 | Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 1234-1242      | 5.8  | 25 |
| 192 | Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , <b>2017</b> , 65, 1683-1692   | 11.2 | 40 |
| 191 | Medical Treatment of Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2017</b> , 38, 686-700   | 3.9  | 6  |
| 190 | Portopulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2017</b> , 38, 651-661  | 3.9  | 16 |
| 189 | Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 50,   | 13.6 | 69 |

|     |   |      |     |
|-----|---|------|-----|
| 188 | Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 50,  | 13.6 | 58  |
| 187 | Exertional dyspnoea in pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2017</b> , 26,  | 9.8  | 17  |
| 186 | Are indexed values better for defining exercise pulmonary hypertension?. <i>European Respiratory Journal</i> , <b>2017</b> , 50,  | 13.6 | 2   |
| 185 | Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , <b>2017</b> , 50,  | 13.6 | 62  |
| 184 | Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 50,   | 13.6 | 298 |
| 183 | Acute decompensated pulmonary hypertension. <i>European Respiratory Review</i> , <b>2017</b> , 26,  | 9.8  | 28  |
| 182 | A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. <i>Journal of Cardiac Failure</i> , <b>2017</b> , 23, 29-35   | 3.3  | 14  |
| 181 | Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 386-398   | 5.8  | 12  |
| 180 | Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study. <i>Journal of Clinical Monitoring and Computing</i> , <b>2017</b> , 31, 903-910  | 2    | 3   |
| 179 | Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. <i>Chest</i> , <b>2017</b> , 151, 106-118  | 5.3  | 36  |
| 178 | SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , <b>2017</b> , 38, 1147-1155 | 9.5  | 44  |
| 177 | A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1457-65   | 2.4  | 9   |
| 176 | Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 1436-44   | 13.6 | 31  |
| 175 | Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. <i>Chest</i> , <b>2016</b> , 149, 353-361   | 5.3  | 46  |
| 174 | Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2016</b> , 149, 1482-93  | 5.3  | 33  |
| 173 | A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica. <i>European Respiratory Review</i> , <b>2016</b> , 25, 93-6  | 9.8  | 6   |
| 172 | Patients' relatives' and practitioners' views of pulmonary arterial hypertension: A qualitative study. <i>Presse Medicale</i> , <b>2016</b> , 45, e11-27  | 2.2  | 14  |
| 171 | Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. <i>Drug Safety</i> , <b>2016</b> , 39, 287-94   | 5.1  | 26  |



|     |   |      |     |
|-----|---|------|-----|
| 170 | Genetic counselling in a national referral centre for pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 541-52  | 13.6 | 63  |
| 169 | Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 3207-18   | 15.9 | 144 |
| 168 | Kinetics of Cardiac Output at the Onset of Exercise in Precapillary Pulmonary Hypertension. <i>BioMed Research International</i> , <b>2016</b> , 2016, 6050193  | 3    | 5   |
| 167 | Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2016</b> , 150, 256-8  | 5.3  | 11  |
| 166 | Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". <i>Circulation</i> , <b>2016</b> , 133, e592-3                            | 16.7 | 4   |
| 165 | Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4911 | 1.8  | 23  |
| 164 | International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. <i>Transplantation</i> , <b>2016</b> , 100, 1440-52               | 1.8  | 188 |
| 163 | BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 1668-1681   | 13.6 | 49  |
| 162 | Beyond a single pathway: combination therapy in pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2016</b> , 25, 408-417   | 9.8  | 38  |
| 161 | Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 1517-1519                                    | 13.6 | 36  |
| 160 | Interferon-induced pulmonary hypertension: an update. <i>Current Opinion in Pulmonary Medicine</i> , <b>2016</b> , 22, 415-20   | 3    | 23  |
| 159 | Pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 1518-34   | 13.6 | 134 |
| 158 | Initial dual oral combination therapy in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 1727-36   | 13.6 | 85  |
| 157 | Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2016</b> , 35, 647-56  | 5.8  | 6   |
| 156 | Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 254-7           | 13.6 | 17  |
| 155 | BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 129-37   | 35.1 | 202 |
| 154 | Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 1469-76                               | 3.8  | 5   |
| 153 | Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. <i>International Journal of Cardiology</i> , <b>2015</b> , 184, 763-765                                       | 3.2  | 1   |

|     |   |      |     |
|-----|---|------|-----|
| 152 | Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. <i>Circulation</i> , <b>2015</b> , 132, 834-47   | 16.7 | 80  |
| 151 | Six-Years Experience With High Priority Allocation Program for Lung and Heart-Lung Transplantation in Pulmonary Hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, S160           | 5.8  | 2   |
| 150 | Systolic and mean pulmonary artery pressures: are they interchangeable in patients with pulmonary hypertension?. <i>Chest</i> , <b>2015</b> , 147, 943-950  | 5.3  | 30  |
| 149 | Validation of two predictive models for survival in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 152-64   | 13.6 | 62  |
| 148 | Criteria for diagnosis of exercise pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 728-37   | 13.6 | 154 |
| 147 | New pharmacotherapy options for pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 2113-31   | 4    | 17  |
| 146 | Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1721-31  | 13.6 | 55  |
| 145 | Effect of macitentan on hospitalizations: results from the SERAPHIN trial. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 1-8  | 7.9  | 42  |
| 144 | Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. <i>American Journal of Cardiovascular Drugs</i> , <b>2015</b> , 15, 13-26                      | 4    | 19  |
| 143 | Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1851-3   | 13.6 | 9   |
| 142 | Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH). <i>Chest</i> , <b>2015</b> , 148, 961A | 5.3  | 3   |
| 141 | Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. <i>Chest</i> , <b>2015</b> , 147, 1385-1394  | 5.3  | 26  |
| 140 | Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1711-20   | 13.6 | 31  |
| 139 | Pulmonary Hypertension Complicating Fibrosing Mediastinitis. <i>Medicine (United States)</i> , <b>2015</b> , 94, e1800  | 1.8  | 32  |
| 138 | Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension. <i>PLoS ONE</i> , <b>2015</b> , 10, e0134221  | 3.7  | 10  |
| 137 | Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2015</b> , 45, 1495-8                                    | 13.6 | 31  |
| 136 | Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1211-4   | 13.6 | 3   |
| 135 | Chronic thromboembolic pulmonary hypertension. <i>Presse Medicale</i> , <b>2015</b> , 44, e409-16   | 2.2  | 15  |

|     |  |      |     |
|-----|--|------|-----|
| 134 | Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2522-33  | 59.2 | 521 |
| 133 | Response to Letter Regarding Article, "Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension". <i>Circulation</i> , <b>2015</b> , 132, e154  | 16.7 | 3   |
| 132 | Chemotherapy-induced pulmonary hypertension: role of alkylating agents. <i>American Journal of Pathology</i> , <b>2015</b> , 185, 356-71   | 5.8  | 116 |
| 131 | EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. <i>Nature Genetics</i> , <b>2014</b> , 46, 65-9  | 36.3 | 259 |
| 130 | Targeted therapies in pulmonary arterial hypertension. <i>Pharmacology &amp; Therapeutics</i> , <b>2014</b> , 141, 172-91  | 13.9 | 128 |
| 129 | Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 915-7  | 13.6 | 76  |
| 128 | Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. <i>Presse Medicale</i> , <b>2014</b> , 43, e345-63           | 2.2  | 34  |
| 127 | Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. <i>International Journal of Cardiology</i> , <b>2014</b> , 172, 561-7 | 3.2  | 24  |
| 126 | EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. <i>American Heart Journal</i> , <b>2014</b> , 167, 210-7  | 4.9  | 46  |
| 125 | The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2014</b> , 8, 84-92  | 4.9  | 7   |
| 124 | Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 641-3   | 13.6 | 8   |
| 123 | Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. <i>European Respiratory Journal</i> , <b>2014</b> , 44, 1069-72  | 13.6 | 33  |
| 122 | Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 1691-7   | 13.6 | 214 |
| 121 | Advances in therapeutic interventions for patients with pulmonary arterial hypertension. <i>Circulation</i> , <b>2014</b> , 130, 2189-208  | 16.7 | 209 |
| 120 | Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2014</b> , 44, 704-13  | 13.6 | 41  |
| 119 | Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment. <i>European Respiratory Review</i> , <b>2014</b> , 23, 505-9   | 9.8  | 3   |
| 118 | Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , <b>2014</b> , 44, 1627-34   | 13.6 | 66  |
| 117 | Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2014</b> , 33, 689-97   | 5.8  | 14  |

|     |  |      |     |
|-----|--|------|-----|
| 116 | Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 1193-205  | 5.5  | 19  |
| 115 | Macitentan and morbidity and mortality in pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 809-18  | 59.2 | 878 |
| 114 | Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , <b>2013</b> , 8, 97  | 4.2  | 168 |
| 113 | Treatment goals of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, D73-81   | 15.1 | 207 |
| 112 | Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2013</b> , 41, 578-87   | 13.6 | 65  |
| 111 | Inflammatory mechanisms in HIV-associated pulmonary arterial hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2013</b> , 34, 645-53  | 3.9  | 11  |
| 110 | Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. <i>European Respiratory Journal</i> , <b>2013</b> , 41, 96-103   | 13.6 | 75  |
| 109 | Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1940-6   | 2.4  | 89  |
| 108 | Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction. <i>Respiration</i> , <b>2013</b> , 85, 471-7  | 3.7  | 19  |
| 107 | Renal replacement therapy in patients with severe precapillary pulmonary hypertension with acute right heart failure. <i>Respiration</i> , <b>2013</b> , 85, 464-70  | 3.7  | 12  |
| 106 | Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy. <i>Chest</i> , <b>2013</b> , 144, 876A | 5.3  | 3   |
| 105 | Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. <i>Chest</i> , <b>2013</b> , 144, 1512-1520  | 5.3  | 18  |
| 104 | Calcium-channel blockers in pulmonary arterial hypertension. <i>Handbook of Experimental Pharmacology</i> , <b>2013</b> , 218, 161-75  | 3.2  | 5   |
| 103 | Calcium-Channel Blockers in Pulmonary Arterial Hypertension. <i>Handbook of Experimental Pharmacology</i> , <b>2013</b> , 161-175  | 3.2  | 5   |
| 102 | Pathways in pulmonary arterial hypertension: the future is here. <i>European Respiratory Review</i> , <b>2012</b> , 21, 321-7  | 9.8  | 83  |
| 101 | Hemodynamics in pulmonary arterial hypertension: current and future perspectives. <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 9S-15S  | 3    | 33  |
| 100 | Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. <i>Journal of Heart and Lung Transplantation</i> , <b>2012</b> , 31, 150-8   | 5.8  | 73  |
| 99  | Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2995-3005   |      | 82  |

|    |   |      |     |
|----|---|------|-----|
| 98 | The study of risk in pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2012</b> , 21, 234-8  | 9.8  | 14  |
| 97 | Pulmonary arterial hypertension in patients treated by dasatinib. <i>Circulation</i> , <b>2012</b> , 125, 2128-37   | 16.7 | 448 |
| 96 | The association between resting and mild-to-moderate exercise pulmonary artery pressure. <i>European Respiratory Journal</i> , <b>2012</b> , 39, 313-8  | 13.6 | 17  |
| 95 | Pulmonary hypertension associated with benfluorex exposure. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 1164-72   | 13.6 | 60  |
| 94 | Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 75-83  | 13.6 | 39  |
| 93 | Pulmonary Arterial Hypertension and HIV and Other Viral Infections. <i>Progress in Respiratory Research</i> , <b>2012</b> , 105-112   |      | 1   |
| 92 | Portopulmonary Hypertension and Hepatopulmonary Syndrome. <i>Progress in Respiratory Research</i> , <b>2012</b> , 113-121   |      |     |
| 91 | Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal. <i>European Respiratory Review</i> , <b>2012</b> , 21, 259-62  | 9.8  | 2   |
| 90 | EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism. <i>European Respiratory Journal</i> , <b>2012</b> , 39, 1549-50  | 13.6 | 9   |
| 89 | Mediastinal fibrosis mimicking proximal chronic thromboembolic disease. <i>Circulation</i> , <b>2012</b> , 125, 2045-7  | 16.7 | 5   |
| 88 | Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. <i>Chest</i> , <b>2012</b> , 142, 869-876  | 5.3  | 40  |
| 87 | Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the SERAPHIN Trial. <i>Chest</i> , <b>2012</b> , 142, 1026A  | 5.3  | 14  |
| 86 | Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?. <i>Presse Medicale</i> , <b>2011</b> , 40, e65-78  | 2.2  | 21  |
| 85 | Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1585-96  | 4    | 19  |
| 84 | Pulmonary hypertension in patients with neurofibromatosis type I. <i>Medicine (United States)</i> , <b>2011</b> , 90, 201-211   | 1.8  | 42  |
| 83 | Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 2456-64 |      | 87  |
| 82 | Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3522-30  |      | 199 |
| 81 | Treatment of pulmonary arterial hypertension with targeted therapies. <i>Nature Reviews Cardiology</i> , <b>2011</b> , 8, 526-38  | 14.8 | 102 |

|    |  |      |      |
|----|--|------|------|
| 80 | Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure. <i>Chest</i> , <b>2011</b> , 140, 1066-1068   | 5.3  | 6    |
| 79 | Pulmonary hypertension associated with portal hypertension <b>2011</b> , 245-250   |      |      |
| 78 | Pulmonary hypertension related to appetite suppressants <b>2011</b> , 236-244  |      |      |
| 77 | Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. <i>Rheumatology</i> , <b>2010</b> , 49, 490-500 | 3.9  | 74   |
| 76 | Pharmacokinetic evaluation of continuous intravenous epoprostenol. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2010</b> , 6, 1587-98  | 5.5  | 14   |
| 75 | Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. <i>Rheumatology</i> , <b>2010</b> , 49, 940-4  | 3.9  | 44   |
| 74 | Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2010</b> , 35, 1294-302  | 13.6 | 83   |
| 73 | Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 549-55  | 13.6 | 456  |
| 72 | Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. <i>Circulation</i> , <b>2010</b> , 122, 1937-47  | 16.7 | 41   |
| 71 | Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , <b>2010</b> , 31, 1898-907   | 9.5  | 139  |
| 70 | Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 181, 851-61   | 10.2 | 209  |
| 69 | Pulmonary veno-occlusive disease: recent progress and current challenges. <i>Respiratory Medicine</i> , <b>2010</b> , 104 Suppl 1, S23-32  | 4.6  | 78   |
| 68 | Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. <i>Respiratory Medicine</i> , <b>2010</b> , 104 Suppl 1, S74-80   | 4.6  | 9    |
| 67 | Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. <i>Circulation</i> , <b>2010</b> , 122, 156-63   | 16.7 | 1035 |
| 66 | HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. <i>Aids</i> , <b>2010</b> , 24, 67-75   | 3.5  | 118  |
| 65 | Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. <i>Chest</i> , <b>2010</b> , 137, 1297-303   | 5.3  | 38   |
| 64 | Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. <i>Current Opinion in Pulmonary Medicine</i> , <b>2010</b> , 16 Suppl 1, S21-6   | 3    | 3    |
| 63 | Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. <i>Respiratory Research</i> , <b>2010</b> , 11, 73   | 7.3  | 66   |

|    |   |      |     |
|----|---|------|-----|
| 62 | Pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , <b>2009</b> , 33, 189-200   | 13.6 | 216 |
| 61 | Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 1204-6  | 13.6 | 22  |
| 60 | Screening for Portopulmonary Hypertension with Transthoracic Echocardiography: Implications for Early Mortality Associated with Liver Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 180, 378-379 | 10.2 | 2   |
| 59 | Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2009</b> , 30, 411-20   | 3.9  | 28  |
| 58 | Pulmonary arterial hypertension and HIV infection. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2009</b> , 30, 440-7  | 3.9  | 16  |
| 57 | Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. <i>European Respiratory Review</i> , <b>2009</b> , 18, 272-90  | 9.8  | 17  |
| 56 | Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , <b>2009</b> , 34, 1348-56   | 13.6 | 69  |
| 55 | Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. <i>Advances in Therapy</i> , <b>2009</b> , 26, 813-25   | 4.1  | 75  |
| 54 | End points and clinical trial design in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S97-S107  | 15.1 | 166 |
| 53 | Updated evidence-based treatment algorithm in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, S78-S84   | 15.1 | 379 |
| 52 | Is pulmonary arterial hypertension really a late complication of systemic sclerosis?. <i>Chest</i> , <b>2009</b> , 136, 1211-1219   | 5.3  | 100 |
| 51 | Pulmonary venoocclusive disease and failure of specific therapy. <i>Chest</i> , <b>2009</b> , 136, 1181; author reply 1181-2  | 5.3  | 7   |
| 50 | Therapeutic advances in pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2008</b> , 2, 249-65   | 4.9  | 30  |
| 49 | Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 177, 108-13  | 10.2 | 324 |
| 48 | Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 177, 1377-83  | 10.2 | 225 |
| 47 | Portopulmonary hypertension: survival and prognostic factors. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 637-43   | 10.2 | 175 |
| 46 | Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. <i>Medicine (United States)</i> , <b>2008</b> , 87, 220-233                                       | 1.8  | 229 |
| 45 | Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2008</b> , 149, 521-30   | 8    | 437 |

|    |  |      |      |
|----|--|------|------|
| 44 | HIV-related pulmonary arterial hypertension: clinical presentation and management. <i>Aids</i> , <b>2008</b> , 22 Suppl 3, S55-62  | 3.5  | 23   |
| 43 | Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 521-31 |      | 261  |
| 42 | Pulmonary vascular abnormalities in cirrhosis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2007</b> , 21, 141-59  | 2.5  | 49   |
| 41 | Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>2007</b> , 49, 1-5                                 | 3.1  | 67   |
| 40 | Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2007</b> , 26, 357-62  | 5.8  | 105  |
| 39 | Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. <i>Human Mutation</i> , <b>2006</b> , 27, 121-32  | 4.7  | 322  |
| 38 | Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , <b>2006</b> , 27, 589-95   | 9.5  | 224  |
| 37 | Pulmonary arterial hypertension in France: results from a national registry. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 173, 1023-30  | 10.2 | 1367 |
| 36 | Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. <i>Gastroenterology</i> , <b>2006</b> , 130, 120-6  | 13.3 | 240  |
| 35 | Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. <i>Chest</i> , <b>2006</b> , 130, 182-9  | 5.3  | 254  |
| 34 | Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. <i>Chest</i> , <b>2005</b> , 128, 622S  | 5.3  | 19   |
| 33 | Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. <i>Anesthesiology</i> , <b>2005</b> , 102, 1133-7; discussion 5A-6A  | 4.3  | 234  |
| 32 | Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. <i>Aids</i> , <b>2005</b> , 19, 1239-40  | 3.5  | 25   |
| 31 | Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. <i>Circulation</i> , <b>2005</b> , 111, 3105-11  | 16.7 | 815  |
| 30 | Bosentan therapy for pulmonary arterial hypertension. <i>Future Cardiology</i> , <b>2005</b> , 1, 299-309  | 1.3  | 3    |
| 29 | Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 1337-48   | 4    | 12   |
| 28 | Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. <i>European Respiratory Journal</i> , <b>2005</b> , 26, 969-72  | 13.6 | 37   |
| 27 | Idiopathic pulmonary hypertension: what did we learn from genes?. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , <b>2005</b> , 22 Suppl 1, S91-100  | 1.1  | 7    |



|    |   |      |      |
|----|---|------|------|
| 26 | Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 170, 1212-7  | 10.2 | 192  |
| 25 | Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. <i>American Journal of Roentgenology</i> , <b>2004</b> , 183, 65-70   | 5.4  | 190  |
| 24 | Automatic quantification of right ventricular function with gated blood pool SPECT. <i>Journal of Nuclear Cardiology</i> , <b>2004</b> , 11, 293-304  | 2.1  | 31   |
| 23 | Diagnosis and differential assessment of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 40S-47S  | 15.1 | 651  |
| 22 | Prostanoid therapy for pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 56S-61S  | 15.1 | 154  |
| 21 | Endothelin receptor antagonists in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 62S-67S  | 15.1 | 125  |
| 20 | Treatment of pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 1425-36   | 59.2 | 1338 |
| 19 | Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. <i>Chest</i> , <b>2003</b> , 124, 247-54  | 5.3  | 221  |
| 18 | Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2003</b> , 167, 1433-9   | 10.2 | 247  |
| 17 | Primary pulmonary hypertension: Current therapy. <i>Progress in Cardiovascular Diseases</i> , <b>2002</b> , 45, 115-28  | 8.5  | 48   |
| 16 | Inhaled iloprost for severe pulmonary hypertension. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 322-9   | 59.2 | 1308 |
| 15 | Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2002</b> , 165, 338-40  | 10.2 | 78   |
| 14 | Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. <i>Radiology</i> , <b>2002</b> , 222, 782-8  | 20.5 | 73   |
| 13 | Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 1496-502 | 15.1 | 478  |
| 12 | Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 780-8  | 15.1 | 1074 |
| 11 | Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. <i>Current Therapeutic Research</i> , <b>2002</b> , 63, 227-246                            | 2.4  | 21   |
| 10 | Risk factors for pulmonary arterial hypertension. <i>Clinics in Chest Medicine</i> , <b>2001</b> , 22, 459-75   | 5.3  | 94   |
| 9  | Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. <i>Lancet, The</i> , <b>2001</b> , 358, 1119-23   | 40   | 1175 |

|   |   |      |     |
|---|---|------|-----|
| 8 | Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. <i>Clinics in Chest Medicine</i> , <b>2001</b> , 22, 451-8  | 5.3  | 132 |
| 7 | Severe pulmonary hypertension in histiocytosis X. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2000</b> , 161, 216-23   | 10.2 | 186 |
| 6 | Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2000</b> , 162, 1493-9 | 10.2 | 78  |
| 5 | Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. <i>Circulation</i> , <b>2000</b> , 102, 2460-2  | 16.7 | 58  |
| 4 | Treatment of pulmonary hypertension secondary to connective tissue diseases. <i>Thorax</i> , <b>1999</b> , 54, 273-7  | 7.3  | 72  |
| 3 | Primary pulmonary hypertension associated with the use of fenfluramine derivatives. <i>Chest</i> , <b>1998</b> , 114, 195S-199S   | 5.3  | 77  |
| 2 | Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. <i>Circulation</i> , <b>1996</b> , 93, 484-8  | 16.7 | 74  |
| 1 | Right heart failure <sup>32-47</sup>  |      |     |